Long-term, Prospective, Observational, Multinational, Parallel-cohort Study Monitoring Safety in Patients With MS Newly Started With Fingolimod Once Daily or Treated With Another Approved Disease-modifying Therapy
Phase of Trial: Phase IV
Latest Information Update: 08 Mar 2017
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms PASSAGE
- Sponsors Novartis
- 03 Mar 2017 Planned End Date changed from 1 Jun 2020 to 28 Nov 2022.
- 03 Mar 2017 Planned primary completion date changed from 1 Jun 2020 to 28 Nov 2022.
- 24 Jul 2012 Planned number of patients changed from 3000 to 3600.